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Aims
Detection of E6 and E7 mRNA transcripts has been shown
to be of higher prognostic value for the evaluation of the
precursor lesions of cervical carcinoma than the detection
of HPV DNA in a number of pilot studies [1-3]. In partic-
ular in low grade lesions, HPV DNA testing has poor dis-
criminating power as to the progression of CIN, thus
leading to considerable overtreatment with ensuing costs
to the health care system. We tested an E6, E7 mRNA
detection system in a multicenter study in Germany for its
usefulness in clinical practice.
Methods
We recruited 334 high-risk ambulatory patients in five
clinics with cervical lesions ranging from low-grade
intraepithelial lesions to invasive cervical carcinoma. Col-
poscopy, conventional cytology, HPV-DNA testing
(Hybrid Capture II, Digene Corp.), HPV-mRNA-testing
(PreTect HPV-Proofer, NorChips AS, Norway) and histo-
logic sampling (biopsies and conisations) were per-
formed.
Results
There were 140 patients WNL, 64 patients with CIN I/II,
98 patients with CIN III and 32 patients with invasive car-
cinoma. HPV-DNA testing was positive in 24%, 78%,
92% and 97%, respectively. E6/E7 mRNA positivity rate
were 8%, 41%, 64% and 94%.
Conclusion
The mRNA-based test showed a higher prognostic value
than DNA-based testing in a high-risk population of sev-
eral dysplasia clinics in Germany. Thus, gene expression
profiling of the viral oncogenes E6 and E7 showed superi-
ority to DNA testing in triaging patients with cervical car-
cinoma precursors.
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